Pa. Appeals Court Hints At Backing $70M Risperdal Verdict

Law360, Philadelphia (August 7, 2019, 3:43 PM EDT) -- Members of a Pennsylvania appeals court pushed back against arguments from a Johnson & Johnson subsidiary on Wednesday that a $70 million compensatory damages award returned in a case over a boy's breast growth allegedly linked to the anti-psychotic drug Risperdal was the result of a runaway jury.

While J&J unit Janssen Pharmaceuticals Inc. has pushed to have the verdict struck down on appeal, with a company attorney tagging it as some 30 times the size of the next-largest award the company has faced over alleged Risperdal-related side effects, members of a three-judge Superior Court panel suggested during a hearing that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS